bluebird bio Reports New Interim Data From Phase 1 HGB-206 Study Of LentiGlobin In Patients with Severe Sickle Cell Disease; All patients (n=4) in Group C with ≥ 3 months follow-up consistently producing ≥ 30% anti-sickling HbAT87Q
Benzinga Newsdesk